

Diagnosis and Management of Peri-prosthetic joint infection

GUIDELINES

Compiled by:

Dr Matthew Blair, Specialist Registrar in Infectious Diseases

Liz Forde, cANP in Infectious Diseases

Dr. Arthur Jackson, Consultant in Infectious Diseases

Dr Karen Fitzmaurice, Consultant in Infectious Diseases and Clinical Microbiology

Prof. James Harty, Consultant in Orthopaedic Surgery

TABLE OF CONTENTS

Introduction	3
Preoperative Care	4
Operative stage and Specimen collection	6
Principles of Antimicrobial therapy	7
Microbiology investigations and interpretation	9
References	10

INTRODUCTION

Definitions

- Prosthetic joint infection (PJI) is an infrequent but serious complication of joint arthroplasty. PJI affect approximately 2% of total knee arthroplasty (TKA) and total hip arthroplasty (THA).¹
- Types
 - Early/Post-operative
 - Late/Haematogenous
 - Chronic
- Definition²:
 - Clinical
 - Sinus tract communicating with prosthesis
 - Purulence surrounding prosthetic joint
 - Microbiological
 - Presence of 2 phenotypically indistinguishable organisms recovered from joint tissue/fluid specimens OR single virulent organism (e.g. *S. aureus*)
 - Histological
 - Acute inflammation on histopathological examination of periprosthetic tissue


Diagnosis

- Diagnosis and medical treatment of PJI is dependent on microbiological sampling.
- Separate instruments should be used to minimize contamination. Each tissue sampled should be transferred to a separate sterile container and labeled.
- Recommended sample sites: capsular tissue, acetabular membrane (for THA), femoral membrane, tibial membrane (for TKA), other tissue (i.e. granulation tissue).³
- Identification of the causative organism may be optimized by the addition of enrichment cultures (i.e. blood culture specimen bottles/other enrichment media).⁴
- For chronic PJI, consider peri-prosthetic biopsy or aspirate in advance of surgery in order to guide therapy (local and systemic).

Antimicrobial therapy

- In general, systemically stable patients with chronic PJI should not receive any antibiotics for 2 weeks prior to operative sampling to optimize culture yield.
- Surgical prophylaxis should not be given in theatre until after appropriate peri-prosthetic joint samples are obtained.
- Infectious Diseases should be consulted for all patients with PJI and should be consulted in the planning stages (pre-operatively) for patients with a history of multiple PJI, a history of difficult-to-treat organisms, culture-negative PJI or drug allergies/intolerances.

PREOPERATIVE CARE



Consider joint aspirate/periprosthetic biopsy
(at discretion of Orthopaedic team)



Does the patient meet criteria for systemic antibiotics?

- Is there signs of haemodynamic instability (shock)?
- Is the patient systemically unwell?
- Is there another indication for antibiotics i.e. pneumonia?
- Are the blood cultures positive?
- Always apply clinical judgement depending on specific scenario and discuss with ID if concerns



YES



Prescribe:

- Vancomycin (25mg/kg loading dose, then refer to MicroGuide Vancomycin dosing & monitoring)
- Tazocin 4.5g QDS* for 48 hours (stop if no gram negatives cultured)

For non-severe penicillin allergy:

- Replace Tazocin with Ceftriaxone 2g od

For severe penicillin Allergy:

- Replace Tazocin with Aztreonam* (2g TDS)

* assumes normal renal function (refer to MicroGuide)




NO



Withhold antibiotics until after specimen collection in theatre

OPERATIVE STAGE AND SPECIMEN COLLECTION



PRINCIPLES OF ANTIMICROBIAL THERAPY IN PJI

Pre-operative antibiotics

- Antibiotics should be with-held to maximize microbiological yield. Ideally, patients should have no antibiotics for 2 weeks before surgery if they are systemically well.
- Unlike elective surgeries, in stable patients with chronic PJI, antimicrobials should not be given in theatre until after appropriate peri-prosthetic joint samples are obtained in order to maximize microbiological yield.
- Where patients are deemed medically unstable or systemically unwell, antibiotics should not be withheld (discuss with ID/Micro). Holding prescribed antibiotics until after joint sampling in theatre may be prudent to optimise yield in patients who have been stabilized.
- If antibiotics are to be administered before sampling in theatre, ensure that non-invasive samples (blood cultures, joint aspirate, sinus tract swabs) are obtained either prior to or very shortly after administration of antibiotics.
- Infectious Diseases should be consulted for all patients with PJI and pre-operatively for patients with a history of multiple PJI, a history of difficult-to-treat organisms, culture-negative PJI or drug allergies/intolerances to empiric regimen (i.e. vancomycin, penicillin). ID will assist with preoperative planning including choice of local antibiotic therapy.
- Difficult-to-treat organisms include MRSA, *Candida*, and Enterococci.
- Consider further investigations such as PET/ Bone scan after discussion with ID.

Empiric therapy

- Early active antimicrobial therapy is associated with reduced biofilm formation and better outcomes in PJI treated with debridement, antibiotics and implant retention (DAIR).⁵
- All patients should receive empiric coverage for gram-positive and gram-negative organisms after sampling.
 - Gram-negative cover (i.e. Piperacillin/tazobactam or ceftriaxone as per above algorithms) should be continued for 48 hours after surgery. If no gram-negative organisms are grown at 48 hours, gram-negative cover can be discontinued.
 - Gram-positive cover (i.e. vancomycin) should be continued for 7 days until reviewed by ID or until results from sampling are available.
- For patients with chronic PJI and a known organism, empiric regimen should include an antibiotic with activity against that organism.
- Antibiotic therapy may be tailored once a pathogen is identified and susceptibilities are known.

Local antimicrobial therapy

- There is evidence that use of antibiotic-loaded spacers improves outcomes in PJI.⁶

- Surgical team should ensure that an antibiotic with appropriate cover for the isolated organism is used. Consult Infectious Diseases for further guidance.

Monitoring

- All patients receiving antimicrobial therapy as an inpatient should have twice weekly FBC, renal/liver profile, CRP.⁷
- Drug specific monitoring:
 - Vancomycin – twice weekly trough levels if within range (refer to Vancomycin dosing and monitoring on MicroGuide)
 - Daptomycin – weekly Creatinine kinase (CK) levels and to hold statins.
 - Gentamicin – daily trough level prior to antibiotic administration
 - Rifampicin – Pharmacy review due to multiple drug-drug interactions. Weekly LFTs.
 - Antifungals – weekly renal/liver profiles.

Outpatient Parenteral Antimicrobial Therapy (OPAT)

- Patients may be referred for OPAT for completion of antibiotic therapy either at home or in a step down convalescence facility if more appropriate and available.
 - For CUH patients :
 - Complete online OPAT referral on iCM &
 - Request ID Consult by ringing ID Consult Registrar (See Staff Directory)
 - For South Infirmery Victoria University Hospital patients:
 - Request ID Consult by ringing ID Consult Registrar via Cork University Hospital switchboard
 - Forward referral request to Infectious Disease Admin Office, Ground Floor, Cork University Hospital
- Decision for IV versus oral therapy to be decided by Infectious Diseases team and all OPAT regimes require ID Consultant approval.
- Contact OPAT nurses to assess suitability BEFORE insertion of PICC line – as a PICC line is the preferred IV access for OPAT
- If suitable and deemed medically fit, OPAT nurse will refer to the national OPAT programme, coordinating OPAT delivery with Community nursing partners availability and advise of OPAT start date.
- Patient remains under the joint care of the Referring Consultant and the OPAT team with an agreed management plan.
 - OPAT Patient Information Videos are available at <https://www.cuh.hse.ie/our-services/our-specialities-a-z/opat/opat-outpatient-parenteral-antimicrobial-service.html>

MICROBIOLOGY INVESTIGATIONS AND INTERPRETATION

- A positive microbiology result is the isolate of either
 - At least 2 phenotypically indistinguishable organisms (e.g. *S. hominis*)
 - 1 virulent organism (e.g. *S. aureus*).
- Surgical team should ensure that an antibiotic with appropriate cover for the isolated organism is used. Consult Infectious Diseases for further guidance.

REFERENCES

-
- ¹ Patel, R. (2023). Periprosthetic Joint Infection. *New England Journal of Medicine*, 388(3), 251-262.
- ² Douglas R. Osmon, Elie F. Berbari, Anthony R. Berendt, Daniel Lew, Werner Zimmerli, James M. Steckelberg, Nalini Rao, Arlen Hanssen, Walter R. Wilson, Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guidelines by the Infectious Diseases Society of America, *Clinical Infectious Diseases*, Volume 56, Issue 1, 1 January 2013, Pages e1–e25, <https://doi.org/10.1093/cid/cis803>
- ³ Atkins, B. L., Athanasou, N., Deeks, J. J., Crook, D. W., Simpson, H., Peto, T. E., McLardy-Smith P, Berendt A.R., Group, T. O. C. S. (1998). Prospective evaluation of criteria for microbiological diagnosis of prosthetic-joint infection at revision arthroplasty. *Journal of clinical microbiology*, 36(10), 2932-2939.
- ⁴ Peel, T. N., Dylla, B. L., Hughes, J. G., Lynch, D. T., Greenwood-Quaintance, K. E., Cheng, A. C., Mandrekar J. N. & Patel, R. (2016). Improved diagnosis of prosthetic joint infection by culturing periprosthetic tissue specimens in blood culture bottles. *MBio*, 7(1), e01776-15.
- ⁵ Veerman K, Raessens J, Telgt D, Smulders K, Goosen JHM. Debridement, antibiotics, and implant retention after revision arthroplasty: antibiotic mismatch, timing, and repeated DAIR associated with poor outcome. *Bone Joint J.* 2022 Apr;104-B(4):464-471. doi: 10.1302/0301-620X.104B4.BJJ-2021-1264.R1. PMID: 35360944.
- ⁶ Cui, Q., Mihalko, W. M., Shields, J. S., Ries, M., & Saleh, K. J. (2007). Antibiotic-impregnated cement spacers for the treatment of infection associated with total hip or knee arthroplasty. *JBJS*, 89(4), 871-882.
- ⁷ Sweeney, E.; Curtin, N.; DeBarra, E.; Burns, K.; O'Neill, E.; Feeney, E.; Jackson, A.; Gavin, P.; Clarke, S.; O'Connell, S. and Muldoon, E.G. (2019) Irish National Guidelines on the Provision of Outpatient Parenteral Antimicrobial Therapy (OPAT). Available at <https://www.idsociety.ie/assets/files/shares/OPAT%20guidelines%20Oct%202019.pdf>